Clinical Trial Detail

NCT ID NCT03163667
Title CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Calithera Biosciences, Inc
Indications

renal cell carcinoma

Therapies

CB-839 + Everolimus

Everolimus

Age Groups: adult senior

No variant requirements are available.